PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis
Presenter: Patrick W. Serruys
Up Next
Presenter: Brian G. DeRubertis
More slides +
Presenter: Robert D. Safian
Presenter: Ulf Landmesser